Neumora Therapeutics (NMRA) Other Accumulated Expenses (2022 - 2026)

Neumora Therapeutics' Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $736000.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 79.95% year-over-year to $736000.0; the TTM figure through Mar 2026 stood at $736000.0 (up 79.95% YoY), while the FY2025 annual figure was $724000.0, up 122.09% from the prior year.
• Other Accumulated Expenses was $736000.0 for Q1 2026 at Neumora Therapeutics, up from $724000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $750000.0 in Q4 2023 to a low of $326000.0 in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $493916.7 across 5 years, with a median of $429000.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses slumped 56.53% in 2024, then soared 122.09% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $408000.0 in 2022, then soared by 83.82% to $750000.0 in 2023, then plunged by 56.53% to $326000.0 in 2024, then jumped by 122.09% to $724000.0 in 2025, then grew by 1.66% to $736000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $736000.0 (Q1 2026), $724000.0 (Q4 2025), and $449000.0 (Q3 2025), per Business Quant data.